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Abstract
Purpose To investigate the potential effect of tolterodine
on the human heart rate variability (HRV). Oral antimu-
scarinic treatment for overactive bladder might signifi-
cantly alter HRV, which is an important predictor for
cardiac and all-cause mortality. Yet, little information
exists regarding the influence of oral antimuscarinics on the
HRV.
Methods Healthy female volunteers were randomly
assigned to either placebo, tolterodine extended release
(ER) 4 or 8 mg. Before and 4 h post treatment, a 10 min
electrocardiogram (ECG) was recorded in supine position.
Frequency domain and time domain analysis of both ECG
measurements resulted in very low frequency (VLF), low
frequency (LF), and high frequency (HF) data, the root
mean square of differences of successive NN (= normal to
normal, i.e. interval between two R-peaks) intervals
(RMSSD), and the standard deviation of the NN intervals
(SDNN).
Results Thirty subjects (mean age: 23.7 ± 2.3 years)
were investigated. Placebo caused no significant HRV
changes. Tolterodine 4 mg significantly increased heart
rate (HR) and significantly decreased VLF. Tolterodine
8 mg significantly decreased HF, VLF, RMSSD and SDNN
and significantly increased HR and LF/HF ratio. The
changes observed with 4 mg were not significantly
different versus placebo, but 8 mg significantly increased
LF/HF as compared to placebo.
Conclusions A single dose of 8 mg tolterodine ER, but
not 4 mg seems to reduce resting HRV versus placebo in
young healthy subjects. This might be particular relevant
for patients with pre-existing cardiac conditions on daily
overactive bladder drug treatment and should be further
investigated in larger trials.
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Introduction
Overactive bladder (OAB) is quite common with an overall
prevalence range from 10 to 17% [1–3] with the incidence
of OAB increasing with age [4, 5].
The first line drug therapy for OAB is oral antimuscar-
inic treatment which is usually administered on a daily
basis for several months or years [6].
Heart rate (HR) elevations are a well known adverse
effect of this class of drugs [7–9] and like OAB, the inci-
dence of cardiovascular diseases increases with age [10]. In
addition, a recent study showed that the prevalence of
cardiovascular comorbidities is significantly higher in
patients with than without OAB and that previous exposure
to medications with antimuscarinic effects was also higher
in patients with OAB [11].
Elevations in HR increase cardiac oxygen demand and
concomitantly decrease cardiac oxygen supply due to
shortening of the diastole [9]. This might be of little rele-
vance for a healthy heart, but patients with cardiac
comorbidities or impaired cardiac autonomic regulation
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might be at risk for cardiovascular events [9, 11]. A recent
cohort study showed that elevated resting HR (rHR) is an
independent predictor for myocardial infarction or coro-
nary death [12].
Another important HR-related indicator of cardiac
autonomic function and predictor of cardiac mortality and
of all-cause mortality is the heart rate variability (HRV)
[13, 14].
However, very little information exists on the effect of
oral antimuscarinic drugs used in daily OAB treatment on
the human HRV. It was therefore our aim to investigate the
effect of the widely used antimuscarinic drug tolterodine
extended release (ER) on the human HRV.
Subjects and methods
Following approval of the local ethics committee, healthy
female volunteers were recruited. Written informed con-
sent of all subjects was obtained prior to inclusion.
A 10 min baseline electrocardiogram (ECG) was
recorded in all subjects. Afterwards, subjects received
either placebo, tolterodine ER 4 mg (Tol4) or 8 mg (Tol8).
Placebo and tolterodine capsules (provided by the phar-
macy of the University Hospital Zurich), were packed
individually for each subject into neutral drug containers.
The sequence of the containers was randomized using a
standard scientific randomizer (http://www.randomizer.
org/form.htm) and documented on a blinding protocol,
which was not known by subjects and investigators. Sub-
jects received their drug container in the same sequence as
they were included into the study, i.e., subject 1 received
container 1, subject 2 received container 2, etc.
Although Tol8 is not the officially approved dose for
OAB treatment, we included Tol8 into the protocol, to
observe a potential dose-dependent effect on the HRV,
which might be especially relevant for patients with neu-
rogenic detrusor overactivity (NDO), who frequently use
higher doses of antimuscarinics to achieve an acceptable
effect on the DO.
Following 4 h-post dosing, a second 10 min ECG was
recorded. A telephone follow-up was performed 2–3 days
after the investigation to check for any side-effects.
Both, pre- and post-dosing ECG measurements were
performed after 30–35 min of rest, with subjects in supine
position. The ECGs were analyzed using frequency domain
and time domain analysis as described in detail previously
[15, 16]. Briefly, the following steps were performed for
the frequency domain analysis: (1) extraction of the middle
5 min section of each 10 min ECG measurement, (2)
detection of R-waves in ECG lead II, (3) calculation of
RR-intervals and generation of discrete event series (DES),
(4) calculation of power spectra from the DES, (5)
calculation of the integral of very low frequency (VLF,
0.003–0.04 Hz), low frequency (LF, 0.04–0.15 Hz), and
high frequency (HF, 0.15–0.4 Hz) ranges. From the LF and
HF values, the LF/HF ratio was calculated. The sum of all
frequency ranges resulted in the 5-min total power (TP).
For the time domain analysis, the mean rHR, the stan-
dard deviation of all NN intervals (SDNN, NN = normal
to normal, i.e., interval between two R-peaks), and the root
mean square of the sum of the squares of differences
between adjacent NN intervals (RMSSD) were calculated.
All analyzing processes were performed using the sci-
entific software Soleasy (ALEA Solutions GmbH, Zurich,
Switzerland).
For comparison of the outcome parameters within the
same group, the Wilcoxon Signed Ranks test was used. An
a of 0.05 was considered as statistically significant.
The Kruskal–Wallis test and subsequently the Mann–
Whitney test were used for statistical analysis between the
three groups either pre- or post-treatment. Due to multiple
comparisons when using the Mann–Whitney test, a had to
be adjusted to 0.025.
All tests were calculated using SPSS 14.0 (SPSS,
Inc., Chicago, IL, USA).
Non-parametric statistical tests were applied, as group
sizes are rather small and a Gaussian distribution of the
data is not given.
Results
Thirty healthy female subjects (mean age: 23.7 ± 2.3
years, mean BMI: 20.5 ± 1.7 kg m-2) were included and
equally randomized among the three groups.
Only minor side-effects were reported in single cases
from all groups 4 h post-dosing or at the follow-up inter-
view. In detail, tiredness was reported from four subjects (3
placebo, 1 Tol8), headache from six subjects (2 placebo, 1
Tol4, 3 Tol8), nausea from two subjects (1 placebo, 1
Tol8), dry mouth from two subjects (1 placebo, 1 Tol4),
and the feeling of increased pressure behind the eye from
one subject in the Tol8 group.
All side-effects were reported as self-limited (12–24 h)
and mild to moderate in intensity.
The median values and interquartile ranges of the pre-
and post-treatment HRV parameters of each group are
summarized in Table 1. No significant differences were
detected between the three groups pre-dosing (rHR:
p = 0.225, TP: p = 0.170, VLF: p = 0.225, LF: p = 0.18,
HF: p = 0.254, LF/HF: p = 0.647, RMSSD: p = 0.151,
SDNN: p = 0.263).
In the placebo group no significant changes between the
pre- and post-dosing HRV parameters were observed
(Table 1).
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Tol4 significantly increased rHR and significantly
decreased VLF (Table 1). The other parameters within this
group did not show any significant changes between pre-
and post-dosing (Table 1).
Tol8 significantly increased rHR and LF/HF ratio and
significantly decreased TP, HF, VLF, RMSSD and SDNN
(Table 1). For the LF parameter, no significant difference
was found within the Tol8 group.
In the comparison between all groups post-dosing, Tol8
significantly increased the LF/HF ratio versus placebo
(p = 0.01) (Fig. 1). No further significant differences were
found between groups post-dosing (rHR: p = 0.348, TP:
p = 0.206, VLF: p = 0.305, LF: p = 0.287, HF:
p = 0.095, RMSSD: p = 0.175, SDNN: p = 0.192).
Discussion
Tolterodine is not selective for a muscarinic receptor sub-
type [17] and can therefore cause cardiac side effects via
the M2 receptors on the heart [8, 18].
Besides M2, other muscarinic receptors (M1, M3 and
M5) have been localized in the heart [8, 19]. Low-dose
Table 1 Summary of the HRV parameters analyzed from the ECG recordings of all subjects, ordered by group and pre- and post-treatment
period
Placebo Tol 4 mg Tol 8 mg
Pre Post Pre Post Pre Post
rHR (bpm) 68.8 (60.2–74.2) 74.7 (62.7–80.5) 59.9 (51.7–67.9) 67.6 (61.2–73.7) 62.6 (58.0–72.6) 72.9 (70.4–78.8)
Sig. p = 0.185 p = 0.047 p = 0.005
TP (ms2) 42.9 (39.6–60.9) 36.5 (34.0–54.0) 62.7 (48.1–81.9) 46.9 (40.0–73.7) 54.9 (38.9–83.2) 41.1 (34.2–42.1)
Sig. p = 0.093 p = 0.074 p = 0.005
VLF (ms2) 42.4 (36.9–54.7) 35.6 (32.9–51.3) 57.7 (43.7–76.9) 44.2 (38.7–58.9) 53.0 (37.7–62.0) 39.5 (33.8–41.0)
Sig. p = 0.169 p = 0.047 p = 0.005
LF (ms2) 1.1 (0.3–1.3) 0.7 (0.4–0.9) 1.5 (0.9–3.8) 1.2 (0.6–2.2) 0.7 (0.5–1.4) 1.0 (0.5–1.3)
Sig. p = 0.285 p = 0.799 p = 0.646
HF (ms2) 0.8 (0.3–2.5) 0.6 (0.3–1.6) 2.4 (1.5–5.2) 1.7 (0.5–2.4) 1.1 (0.6–5.1) 0.3 (0.1–0.6)
Sig. 0.139 p = 0.114 p = 0.028
LF/HF 1.1 (0.6–1.4) 1.0 (0.8–1.9)# 0.7 (0.4–1.1) 1.3 (0.7–2.0) 0.9 (0.2–1.6) 2.9 (2.4–4.6)#
Sig. p = 0.508 p = 0.093 p = 0.007
RMSSD (ms) 47.5 (32.2–76.9) 42.5 (28.8–76.3) 102.88 (55.6–125.5) 69.2 (31.9–92.4) 75.5 (36.7–120.9) 33.1 (16.2–44.6)
Sig. p = 0.386 p = 0.114 p = 0.009
SDNN (ms) 62.6 (37.0–74.6) 45.4 (39.0–71.0) 83.2 (61.7–119.0) 67.0 (44.7–85.0) 63.1 (59.2–114.1) 43.2 (37.4–56.9)
Sig. p = 0.241 p = 0.169 p = 0.005
Presented are median (interquartile range) values
rHR resting heart rate, TP 5 min total power, VLF very low frequency, LF low frequency, HF high frequency, LF/HF low frequency/high
frequency ratio, RMSSD root mean square of the sum of the squares of differences between adjacent RR intervals, SDNN standard deviation of all
RR intervals. Sig. significant difference between pre- and post-treatment within each group (Wilcoxon Signed Ranks test)
# p = 0.01 (Mann–Whitney test), difference between placebo and tolterodine 8 mg group post treatment for LF/HF. All other parameters
showed neither pre- nor post-treatment any significant difference between groups
Fig. 1 LF/HF data for each group, sorted by pre (white boxplots) and
post (blue boxplots) treatment period. The boxplots demonstrate
minimum, 25% percentile, median, 75% percentile, and maximum.
#p = 0.01. Tol tolterodine
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muscarinic antagonists might cause different effects via
M1 than M2 (i.e., HR decrease) [19]. However, choliner-
gically mediated HR regulation is mainly regulated by M2
receptors and the exact functional role of the non-M2
receptors in the heart is rather speculative and needs to be
further clarified [7, 8].
Anticholinergic influence on the HRV has been dem-
onstrated in human subjects by Pentilla¨ et al. [20], showing
a reduction in HF power of 99% after a single intravenous
injection of 10 lg kg-1 atropine or glycopyrolate. These
results are not surprising as the HF spectrum almost
exclusively reflects the parasympathetic input to the heart
[15, 21], which is reduced or inhibited after the intravenous
anticholinergic application [20]. A similar effect was
observed in our study group for Tol8 with a significant
decrease in the HF spectrum post-medication.
Another important frequency domain parameter is the
LF, which is influenced by both parasympathetic and
sympathetic cardiac input [15, 21]. LF did not significantly
change in any group and it might be possible that the
influence of tolterodine on the parasympathetic system is
strong enough to decrease the HF spectrum but does not
alter the LF spectrum, as it reflects also sympathetic input.
The parasympathetic nervous system (PNS) and the
sympathetic nervous system (SNS) are antagonists and
cardiac input from both is usually never in a complete
equilibrium. Rather, there is a constant variability reflect-
ing the ability of the organism to rapidly adapt the car-
diovascular system to changing needs in response to a
broad range of internal and external stimuli [22]. A
decrease of one antagonist (e.g., PNS) causes a relative
increase of the other antagonist (e.g., SNS), which is why
the LF/HF ratio, an indicator of sympathovagal balance
[15, 21], significantly increased after Tol8.
Whilst the intrinsic heart rate is influenced by both the
PNS and SNS, the resting heart rate is mainly dependent on
the parasympathetic tone [8], which explains why the rHR
is significantly elevated after Tol8 and Tol4, although
subjects were in the same recumbent position during the
pre- and post-dosing measurements. These rHR findings
are in line with the findings from a large randomized
controlled study investigating tolterodine and darifenacine
in healthy subjects older than 50 years, showing a signifi-
cantly increased HR after Tol4 [7]. The results of
Olshansky et al. [7] show, in contrast to our rHR results, a
significant increase in HR after tolterodine dosing versus
placebo. This difference might be due to the multiple dose
investigation in the Olshansky study as compared to a
single dose investigation in our study [7].
The physiological basis of the VLF component is less
clear, although earlier studies described that VLF is a more
powerful risk predictor in cardiovascular disease than HF
or LF [23]. Some authors suggest it may represent the
influence of the peripheral vasomotor and renin-angioten-
sin systems [15].
Regarding the time domain parameters, RMSSD repre-
sents a measure of the variability of the interval between
successive beats and mainly reflects parasympathetic
activity [15, 16, 22]. Therefore, a reduction in RMSSD can
be expected after application of antimuscarinic drugs, as
observed in the Tol8 group. This result is again in agree-
ment with the findings from Pentilla¨ et al. [20], who
demonstrated a RMSSD decrease of 97% after intravenous
injection of atropine and glycopyrolate. The SDNN is a
more simple but unspecific indicator of the total amount of
variability, which likewise decreases in response to anti-
cholinergic influence on the heart, as again demonstrated
by the results of the Tol8 group. A reduction of RMSSD or
SDNN generally implies a reduction in HRV, which could
also be observed in the reduction of the total spectral power
in the Tol8 group.
A reduced HRV has been associated with a poor prog-
nosis of cardiovascular disease, an increased risk of inci-
dent myocardial infarction, cardiovascular mortality, and
death from other causes in the general population [14].
Previous studies however, linking HRV to cardiovascular
outcomes, have looked at basal parameters. Whether drug-
induced changes of HRV play a similar role is not fully
clear.
Although Tol8 showed a significant effect on nearly
all HRV parameters within this group (Table 1), only the
increase in LF/HF appeared significantly different in
comparison to the placebo group. This is probably due to
the high interindividual variability in combination with
the quite small group sizes [20]. However, the effect of
Tol8 on LF/HF seems strong enough to show significant
differences between groups even with these group sizes.
This increase in the LF/HF ratio indicates a significant
shift in the autonomic balance towards a sympathetic
predominance on the heart, which can have unfavorable
cardiac effects if this condition were to persist for longer
terms. As the 8 mg dose is not approved for OAB
treatment and therefore rarely used, those results might
be irrelevant for the usual non-neurogenic OAB popu-
lation. However, patients with NDO usually require
higher antimuscarinic doses or a combination of
antimuscarinic drugs [24, 25]. The underlying disease in
NDO (e.g., spinal cord injury, multiple sclerosis) often
causes some degree of autonomic dysfunction that can
also affect the heart [26, 27], resulting amongst others in
elevated HR [27]. Thus, a high dose antimuscarinic
treatment might expose those patients to an increased
cardiac risk.
In the Tol4 group, none of the post-treatment HRV
values—including rHR—were significantly different com-
pared to the post-treatment values of the placebo group.
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However, it cannot be stated that Tol4 does not have
any relevant influence on the HRV, as VLF and rHR
values are significantly altered post treatment in the
4 mg group.
It has to be considered that only a single dose of
tolterodine ER was investigated and a development of
tolerance towards antimuscarinic cardiac effects might
occur with chronic dosing. Thus, effects observed in a
single-dose study might overestimate HR effects during
long term treatment, although steady state plasma levels
are on average higher than with a single dose [28]. To
our knowledge there is no published study specifically
investigating changes in heart rate over time in regard to
antimuscarinic treatment. However, the results of the
study by Olshansky et al. [7] showed a significant
increase in HR with tolterodine compared to placebo
even after 7 days. Moreover, a study, investigating car-
diac risks under respiratory medications, showed that
supraventricular tachycardia was associated with long
term antimuscarinic treatment rather than with short term
treatment [29].
Although significant elevations of HR after Tol4 versus
placebo have been demonstrated in a population[50 years
of age [7], an extrapolation of our findings to the elderly,
more OAB relevant population, has to be regarded cau-
tiously as elderly patients might react differently to
antimuscarinic drugs than young subjects due to potential
aging related changes in atrial muscarinic receptor density
and function [30].
Nevertheless, it is well established that with increasing
age, the HRV decreases [16] and the incidence for car-
diovascular diseases increases [10]. This might be espe-
cially important considering that the incidence of OAB,
and subsequently the incidence of antimuscarinic drug
treatment, also increase with age [4, 5]. Together, these
conditions and the well-established relationships between
age, increasing HR, and mortality/morbidity rates can
make patients with OAB and concomitant cardiovascular
diseases more vulnerable to the cardiac side-effects of
antimuscarinics [11].
Adverse events on the heart due to antimuscarinic OAB
treatment might remain undiscovered as they are usually
not as obvious as the antimuscarinic effect on the salivary
glands, causing dry mouth.
We would therefore encourage the implementation of
HRV evaluation in future clinical trials with antimuscarinic
drugs to gain more insight about possible adverse cardiac
effects of these drugs and its clinical relevance in a larger
patient population. This investigation of the influence of an
oral antimuscarinic drug, used in OAB treatment, on the
HRV provides useful first results and a basis for further
larger investigations.
Conclusions
Although VLF and rHR are significantly altered after a
single dose of Tol4, which might be of prognostic value, it
seems not to significantly alter the HRV or rHR versus
placebo in healthy young female subjects. A single dose of
Tol8, however, seems to reduce HRV and showed a sig-
nificant reduction in LF/HF as compared to placebo.
Although Tol8 is not the recommended and approved dose
in OAB treatment, these findings can be relevant for the
daily therapy of patients with pre-existing cardiac disorders
and patients with NDO, requiring higher antimuscarinic
doses, and need to be further investigated by implementing
the HRV analysis in larger future clinical trials with
antimuscarinic drugs for OAB treatment.
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